Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Sorry. When I put it in comic book form a small portion might penetrate into than cranium (sorry again-big word, let's call it a brain pan) of yours.
You are a paid hack who fabricates petty bullshit. There is no other reason to explain the absurdity of your posts.
"May see 0012-0013 by the end of the day!"
"we doubt that shareholders will hear about it. We expect it will be just like when UEEC applied for PMA approval for Class III in late 2017, there will just not be any updates, like it never happened."
In any event, I doubt he is holding shares. He is more the type who dupes others.
When he has ever posted anything accurate and relevant? Thanking Lamstein, in this instance, was as strong a clue as can be that it would not be both.
Can you state what the actual financial impact will be?
How many weeks has it been put off?
On pure bullshit and hype.
Very telling of an obvious scam when intimidation and insulting attacks are substituted for rational, logical, and thoughtful substance. Who are the clowns and dbags forcefully suckering people out ot their hard earned money?
Repeat this again for the dbags in the back! I thought foreskin sealshin was the biggest dbag but this shoondale may be the biggest clown on the board yet.
Posters with few posts, using expressiveness_and_grammar similar to long term posters are beyond suspect.
Shodburrito
Level Icon
Followers 0
Posts 3
Boards Moderated 0
Alias Born 09/12/2023
Okay, I'm done being nice. Stop blatantly scamming people.
Reguritated bullshit. PMA bait & switches since 2017...
https://www.otcmarkets.com/filing/html?id=12414685&guid=4td-kaJ6H_M4B3h#UEEC_EX991_HTM
"FDA Selects HemoStyp ® for CtQ Pilot Program
Henderson, Nevada – December 4, 2017 –United Health Products, Inc. (UHP) (OTC: UEEC), manufacturer and marketer of HemoStyp®, a patented hemostatic gauze for the healthcare and wound care sectors, today announced that it is proceeding with its application for HemoStyp under the FDA’s new and innovative CtQ Pilot Program. The FDA selected UHP’s HemoStyp as only one of nine participants for the program. UHP management has scheduled its first face-to-face meeting with FDA experts for January 17, 2018 to provide the agency with whatever information it needs to advance the application for premarket approval (PMA).
The FDA has stated that it intends to work collaboratively with pilot program participants during the review of their PMA submission to define characteristics of the device that are critical to product quality, and how these characteristics are controlled in design and manufacturing prior to the postmarket inspection. For pilot program participants, the FDA would forego conducting the standard PMA preapproval inspection, and a postmarket inspection focusing on the PMA applicant’s implementation of the critical to quality characteristics would be conducted instead.
The CtQ Pilot Program was created to identify products that have a chemical makeup of demonstrated safe interaction with the body –as evidenced by years of prior product usage and studies-- to be approved for Class III internal surgical use. The program’s intent is to allow products that have demonstrated repeated safe interaction to enter the market in a more efficient manner. This application will run simultaneously with the company’s prior Class II application for expanded indication. The market for 2017 internal surgical market for hemostatic products is estimated at in excess of seven billion dollars, and is expected to grow at 7.1% over the next few years, to reach more than $8.3 billion by 2022. (http://industryarc.com/Report/15189/hemostats-market.html)
Concurrent with its CtQ Pilot Program participation, UHP reaffirms that its current Class II application – Expanded Indication submission with the US FDA-- continues to progress, and is in an advanced stage of review
About Premarket Approval Application Critical to Quality (PMA CtQ) Pilot Program
Top-quality medical devices help the FDA better protect and promote public health. And one of the top priorities for FDA’s medical devices center is a focus on quality.
More specifically, the FDA is working with stakeholders—industry, health care providers, patients, payers, and investors—to build a strong Case for Quality.
This program allows the FDA to identify device manufacturers that consistently produce high-quality devices. By doing so, we can better focus our resources helping other manufacturers raise their level of quality. This program also helps the FDA identify and promote practices that support consistent quality manufacturing, and align our regulatory, enforcement, compliance approaches with those practices.
The FDA launched the Case for Quality in 2011 following an in-depth review of device quality data and feedback from both FDA and industry stakeholders. The FDA’s analysis flagged certain widespread or common manufacturing risks that impact product quality. The review also showed manufacturers that focus on and manage those risks often become more productive, receiving fewer complaints, needing to open fewer CAPAs and investigations, and having lower quality-related product costs than their competitors.
In simple terms, the review identified that an investment in quality has long-term payoffs."
Again, it was filmed in August. It did not appear on the BG website until September. By my math, that is 7 months tops. Maybe by your math it comes out to a year.
It has not changed for a year. It could be there forever. Meaningless until we heart something other than a web page.
You must not know much about his reputation. He's never made even a penny in revenue for any company.
Fully funded? He didn't do anything but sell shares
But what is the most alarming to us in the 10/18/19 announcement is that the PR went silent on the very important product safety outcomes. From the UEEC clinical protocol, described on its clinicaltrials.gov page we learned about four secondary study outcomes:
Source: clinicaltrials.gov
While the Primary outcome and the Secondary outcome #1 in the UEEC study protocol are efficacy related, the Secondary #2, #3, and #4 outcomes are all safety outcomes and are of critical importance for FDA approval. The October 18th PR only addresses success of the Primary outcome and Secondary outcome #1. The PR didn't say if the study has shown a non-inferiority or superiority of HemoStyp vs Surgicel in the secondary outcomes #2-4. The history of UEEC only disclosing positive news makes us believe that the omission of results relevant to outcomes #2-4 could have been on purpose, because the clinical study likely showed the inferior performance of HemoStyp vs Surgicel in these outcome measures.
The statistician was very specific to claim non-inferiority and superiority of HemoStyp only in the initial hemostasis after application of HemoStyp to the wound. It is silent on what has happened after the initial hemostasis was achieved.
HemoStyp, according to UEEC, quickly dissolves in an aqueous environment due to its unique degradation properties. We can find this on the company’s website.
From UEEC’s product testing page:
The data obtained during analysis of sample UHP Box of 2” x 2” Pouches indicates the material begins to dissolve in water within one minute. The sample is completely dissolved within 24 hours. Not enough material remains for analysis at the 24 hour time point.
If HemoStyp dissolves too soon, the surgical wound would start bleeding again, and this would be a very serious safety issue.
Imagine a major disaster when bleeding re-occurs after the surgeon has already closed the outmost patient skin layer! The outcomes 2-4 directly address this key safety concern, describing in quantitative terms how well the initially achieved hemostasis is maintained during the surgery. Outcome 4 is about the failure of initial hemostasis, as measured in reoperations, during the one month after surgery. It seems to us that a hemostatic agent that is quick to achieve initial hemostasis, but rapidly dissolves and may frequently fail later resulting in recurrence of bleeding, is a major health hazard. Why would the FDA approve HemoStyp, if it indeed fails to maintain hemostasis, knowing that Surgicel is already a reasonably effective and safe FDA approved product?
From all these observations, we conclude that the clinical study of HemoStyp versus Surgicel was likely a failure. However, if and when its PMA application" gets rejected, we doubt that shareholders will hear about it. We expect it will be just like when UEEC applied for PMA approval for Class III in late 2017, there will just not be any updates, like it never happened."
Are you serious or bullshitting around? I think you better look up the definition of slander. Below your quote is mine. Where is the slander? I will stand by what I said. There is more hype than necessary for a deal of substance from the SAPX end. Let's see what happens. I asked several times, in other posts, what could possible go wrong? Let us see this play out now. I'm especially interested to see the financial impact this will have on Seven Arts, in the end, if this deal goes through. Hey, I hope you guys make out. I just still have my strong doubts.
To be clear, Are you suggesting that mega billion dollar LionsGate , now named in the 8-K filed deal with SAPX, is not "Legitimate"?
I would not want to miss understand you slanderous claim.
No legitimate business puts out tweets this frequently with zero substance behind them. They usually keep their mouths shut until something of substance is going to be announced. It wreaks of someone trying to prop up the share price artificially. It becomes clearer by the tweet or time. If there was anything to announce; it would be announced. Instead, there is one excuse after another with one delay after another. I shouldn't have to explain this to anyone with "sense" as you call them.
OK angels, how do you figure Jason is sabotaging HAD? The only thing he could have done is withhold financing. And that was not the case. HAD was fully funded. Not everything is Jason's fault. The last time I saw anything you could misconstrue as a misstep was the failed crypto endeavor. Did you forsee the crypto collapse? Jason did not. In my case, I cannot fault him because I did not see it either. How do you figure Jason is responsible for lack of network programming? That seems to me to be Blagman's responsibility. What are you seeing here?
Drilling for oil? They should have been drilling a hole in your skull to proceed with the lobotomy.
Knock yourself out Sporty. It won't bother me. You never know what you are talking about anyway. It shows. And the stock price will eventually follow the company's performance in any event. You must be feeling a great deal of heat for losing your clients' money on this scam, trying to manipulate the price, and failing to recruit new suckers into this Ponzi Scheme. Show everyone how a spoiled, manipulative broker throws a tantrum. You are intellectually incapable of adding anything of value other than this anyway.
Sporty is a spoiled crooked broker who bilks and intimidates people. Knock yourself out with the bullshit Sporty. Have fun throwing tantrums. Since your threatening PM's don't work, this won't either. You don't know what you are talking about in any event. I'm more amused by how anxious you are to make a jackass out of yourself. Are you feeling heat for losing your clients' money? I'm going to enjoy watching you sweat.
Disregard me. What conclusions have the FDA_&_SEC drawn? Are they verbose negative opinions and conclusions based on what they believe to be facts? Are they to be dismissed?
What you believe to be the reality. What you believe has actually transpired. I am not saying you are wrong. I am not saying you are right. I am simply observing very verbose negative opinions that are conclusions based on opinions of what you believe to be the relevant facts. There appears to be a goal. I’m just not sure what the goal is.
There are longs, myself included, that are in this until the end.
We are not going to change our position no matter what, so this constant bashing of the company and its management gets to be monotonous, redundant and not productive.
I wish you all the best in your endeavors. This post is rhetorical. I don’t need a response, but I am sure I will get one. Good day.
What is the reality of what has occurred right along? What has actually transpired?
"From all these observations, we conclude that the clinical study of HemoStyp versus Surgicel was likely a failure. However, if and when its PMA application gets rejected, we doubt that shareholders will hear about it. We expect it will be just like when UEEC applied for PMA approval for Class III in late 2017, there will just not be any updates, like it never happened."
The post below describes the "clinical trial" in far more detail than I would. Basically it is a sham posted on a website in which unverified and unreviewed data is posted on the website. The proof in the pudding is that no PMA has ever been approved by the FDA and no FDA document denying the PMA has ever been made available to either shareholders or the public. As I stated earlier; legitimate clinical trials are held at numerous prestigious hospitals with multiple renowned surgeons involved.
"United Health Product’s PRs Describing Its HemoStyp PMA Application Process Are Bizarre, Suggesting A Denial Is Likely
UEEC’s announcement of the PMA submission was released on 10/4/19 stating:
UEEC today announced that it has submitted a Premarket Approval (PMA) application for Class III approval to the FDA for HemoStyp.
This was seemingly very significant news about an important milestone concluding clinical study data analysis and submission. The text of the announcement was, however, very generic and reserved. It further states:
The PMA program confirms the safety and efficacy of a product. If approved, UHP expects that HemoStyp will be authorized for use in surgical procedures in abdominal, cardiovascular, thoracic and vascular surgeries per UHP's PMA filed Instructions For Use.
This October 4th PR mentions nothing about the results of the clinical studies, simply noting that the FDA submission has occurred.
A pre-market application (PMA) application is a very detailed and stringent process. As described in drugwatch.com, the PMA includes:
Source: drugwatch.com
Therefore, the October 4th PMA submission should have included clinical data, including a statistical analysis of its results.
Then, on 10/18/19, a relevant, yet bizarre, PR was announced, claiming positive results of the HemoStyp clinical study. We are puzzled because this announcement comes two weeks after the PMA submission on 10/4/19.
The PR says the final analysis report has been received, and it is from an independent reviewer (does “independent” mean that UEEC didn't pay for this analysis?). It further states:
In summary the independent statistical reviewer (website here) stated:
“For the primary analysis comparing HemoStyp versus Surgicel for hemostasis in 10 minutes, both non-inferiority and superiority were satisfied in both ITT population and PP population. For the secondary analysis, HemoStyp was significantly better than Surgicel with respect to the percentage achieving hemostasis at 2 minutes, 5 minutes, and 10 minutes.”
It further states:
UEEC... today announced that it has received the final report from an independent review of the results of its human clinical trial.
The way the above sentence is worded, it seems as though UEEC had just received the statistical results on October 18 or a day before. It doesn't say that this report was received and sent to the FDA 2 weeks earlier on October 4th. But if it was in fact sent to the FDA in tandem with the October 4th submission, then it is strangely communicated.
Why would they do the analysis after they already sent the application? There is such a thing as a PMA Amendment if the applicant is revising existing information or providing additional information. But UEEC didn’t say that they were doing a PMA Amendment. It is sometimes required to continue statistical analysis after the PMA submission if the clinical study is continuing and the longer patient follow-up is recorded. But according to the UEEC protocol, the follow-up was 30 days and that was finished long ago.
Because this “independent” statistical reviewer apparently gave its analysis after UEEC already submitted its application to the FDA, we would take it with a grain of salt. If it were a relevant review, it should have been included in the PMA application on October 4th. If this analysis was not included, we also wonder then what analysis was included and why the results of that analysis were not mentioned in the PR from October 4th.
But what is the most alarming to us in the 10/18/19 announcement is that the PR went silent on the very important product safety outcomes. From the UEEC clinical protocol, described on its clinicaltrials.gov page we learned about four secondary study outcomes:
Source: clinicaltrials.gov
While the Primary outcome and the Secondary outcome #1 in the UEEC study protocol are efficacy related, the Secondary #2, #3, and #4 outcomes are all safety outcomes and are of critical importance for FDA approval. The October 18th PR only addresses success of the Primary outcome and Secondary outcome #1. The PR didn't say if the study has shown a non-inferiority or superiority of HemoStyp vs Surgicel in the secondary outcomes #2-4. The history of UEEC only disclosing positive news makes us believe that the omission of results relevant to outcomes #2-4 could have been on purpose, because the clinical study likely showed the inferior performance of HemoStyp vs Surgicel in these outcome measures.
The statistician was very specific to claim non-inferiority and superiority of HemoStyp only in the initial hemostasis after application of HemoStyp to the wound. It is silent on what has happened after the initial hemostasis was achieved.
HemoStyp, according to UEEC, quickly dissolves in an aqueous environment due to its unique degradation properties. We can find this on the company’s website.
From UEEC’s product testing page:
The data obtained during analysis of sample UHP Box of 2” x 2” Pouches indicates the material begins to dissolve in water within one minute. The sample is completely dissolved within 24 hours. Not enough material remains for analysis at the 24 hour time point.
If HemoStyp dissolves too soon, the surgical wound would start bleeding again, and this would be a very serious safety issue.
Imagine a major disaster when bleeding re-occurs after the surgeon has already closed the outmost patient skin layer! The outcomes 2-4 directly address this key safety concern, describing in quantitative terms how well the initially achieved hemostasis is maintained during the surgery. Outcome 4 is about the failure of initial hemostasis, as measured in reoperations, during the one month after surgery. It seems to us that a hemostatic agent that is quick to achieve initial hemostasis, but rapidly dissolves and may frequently fail later resulting in recurrence of bleeding, is a major health hazard. Why would the FDA approve HemoStyp, if it indeed fails to maintain hemostasis, knowing that Surgicel is already a reasonably effective and safe FDA approved product?
From all these observations, we conclude that the clinical study of HemoStyp versus Surgicel was likely a failure. However, if and when its PMA application" gets rejected, we doubt that shareholders will hear about it. We expect it will be just like when UEEC applied for PMA approval for Class III in late 2017, there will just not be any updates, like it never happened."
You misinterpreted. I quoted you speaking to me and said my opinion was shared by the SEC and FDA.
"Your opinion"
"The U.S. government does not review or approve the safety and science of all studies listed on this website."
"certain deficiencies in its Premarket Approval (PMA) application that were identified by the FDA in 2021. These were largely related to the need for standardized procedures for our manufacturing process, and quality assurance procedures for finished, customer ready products."
Still waiting for clinical submission link...and waiting....
I have the feeling I will be waiting forever just like the wait for explanation of why all the past PMA's failed....
I have linked to that 10-K in numerous posts today. It answers none of the questions I have asked. It merely creates more questions I am asking. There is nothing about clinical trials or any explanation of 7 years worth of failed PMA's.
Let me return the favor. Here is a link that actually explains what is going on:
https://www.sec.gov/files/litigation/complaints/2022/comp25413.pdf
I post facts with links. Where's your link?
"Hey MORON, we have a full clinical submission on 3/20/24. You post nothing but BullShit!"
What has happened with UHP PMA's since 2017? Although we never hear about it, the reality of the situation is every time a PMA gets filed from United Con Artists, it gets summarily rejected. And, as always, the next time will be different. The reality we are dealing with is that the FDA never approves this product. We have no idea why.
"In response to the FDA’s comments and questions to our 2021 and 2022 PMA submissions, we have developed and incorporated several product design, manufacturing and quality assurance procedures into our production process. Upon completion of certain finished product testing that is being conducted by outside laboratories we will submit a revised application to the FDA. There can be no assurance that our revised application, once resubmitted, will lead to a successful FDA decision regarding a PMA"
"FDA Selects HemoStyp ® for CtQ Pilot Program
Henderson, Nevada – December 4, 2017 –United Health Products, Inc. (UHP) (OTC: UEEC), manufacturer and marketer of HemoStyp®, a patented hemostatic gauze for the healthcare and wound care sectors, today announced that it is proceeding with its application for HemoStyp under the FDA’s new and innovative CtQ Pilot Program. The FDA selected UHP’s HemoStyp as only one of nine participants for the program. UHP management has scheduled its first face-to-face meeting with FDA experts for January 17, 2018 to provide the agency with whatever information it needs to advance the application for premarket approval (PMA).
The FDA has stated that it intends to work collaboratively with pilot program participants during the review of their PMA submission to define characteristics of the device that are critical to product quality, and how these characteristics are controlled in design and manufacturing prior to the postmarket inspection. For pilot program participants, the FDA would forego conducting the standard PMA preapproval inspection, and a postmarket inspection focusing on the PMA applicant’s implementation of the critical to quality characteristics would be conducted instead.
The CtQ Pilot Program was created to identify products that have a chemical makeup of demonstrated safe interaction with the body –as evidenced by years of prior product usage and studies-- to be approved for Class III internal surgical use. The program’s intent is to allow products that have demonstrated repeated safe interaction to enter the market in a more efficient manner. This application will run simultaneously with the company’s prior Class II application for expanded indication. The market for 2017 internal surgical market for hemostatic products is estimated at in excess of seven billion dollars, and is expected to grow at 7.1% over the next few years, to reach more than $8.3 billion by 2022. (http://industryarc.com/Report/15189/hemostats-market.html)
Concurrent with its CtQ Pilot Program participation, UHP reaffirms that its current Class II application – Expanded Indication submission with the US FDA-- continues to progress, and is in an advanced stage of review
About Premarket Approval Application Critical to Quality (PMA CtQ) Pilot Program
Top-quality medical devices help the FDA better protect and promote public health. And one of the top priorities for FDA’s medical devices center is a focus on quality.
More specifically, the FDA is working with stakeholders—industry, health care providers, patients, payers, and investors—to build a strong Case for Quality.
This program allows the FDA to identify device manufacturers that consistently produce high-quality devices. By doing so, we can better focus our resources helping other manufacturers raise their level of quality. This program also helps the FDA identify and promote practices that support consistent quality manufacturing, and align our regulatory, enforcement, compliance approaches with those practices.
The FDA launched the Case for Quality in 2011 following an in-depth review of device quality data and feedback from both FDA and industry stakeholders. The FDA’s analysis flagged certain widespread or common manufacturing risks that impact product quality. The review also showed manufacturers that focus on and manage those risks often become more productive, receiving fewer complaints, needing to open fewer CAPAs and investigations, and having lower quality-related product costs than their competitors.
In simple terms, the review identified that an investment in quality has long-term payoffs."
No legitimate business puts out tweets this frequently with zero substance behind them. They usually keep their mouths shut until something of substance is going to be announced. It wreaks of someone trying to prop up the share price artificially. It becomes clearer by the tweet or time. If there was anything to announce; it would be announced. Instead, there is one excuse after another with one delay after another. I shouldn't have to explain this to anyone with "sense" as you call them.
We went from no one was working before Easter to an additional part could mean even "greater significance here". Oh boy, oh boy, oh boy!!!!!
I wonder why this prevents the initial part from being announced? I get the distinct impression this dude and his insiders are dumping now, after they inflated it, and require suckers to buy while they are dumping.
"We can provide no assurances that our Class III application for internal surgical procedures in the U.S. market will be approved by the FDA."
"There will be no failure. Only epic morons think this."